drug
repurpos
strategi
consid
manag
covid
among
identifi
drug
baricitinib
becom
keen
interest
research
abil
inhibit
viral
assembl
prevent
associ
protein
kinas
associ
endocytosi
import
human
receptor
sar
glycoprotein
human
angiotensin
convert
enzym
novel
corona
viru
similar
glycoprotein
may
also
target
angiotensinconvert
enzym
angiotensin
convert
enzym
predominantli
avail
lower
respiratori
tract
especi
lung
alveolar
epitheli
cell
cell
prone
viral
infect
like
sar
corona
viru
cell
might
help
possibl
viral
reproduct
transmiss
endocytosi
associ
protein
kinas
potenti
promot
endocytosi
help
viral
assembl
intracellular
matrix
cyclin
g
associ
kinas
anoth
regul
endocytosi
baricitinib
anoth
drug
potenti
option
manag
novel
corona
virus
baricitinib
inhibit
ap
associ
protein
kinas
well
cyclin
g
associ
kinas
therebi
prevent
endocytosi
reduc
viral
assembl
baricitinib
inhibitor
janu
kinas
jak
jak
therefor
might
help
manag
inflamm
sever
studi
suggest
use
baricitinib
treat
covid
studi
suggest
baricitinib
initi
patient
absolut
neutrophil
count
less
cellsl
similarli
initi
patient
absolut
lymphocyt
count
less
cellsl
epidemiolog
studi
carri
valu
select
patient
closer
threshold
level
baselin
tabl
epidemiolog
studi
report
absolut
lymphocyt
count
nonsurvivor
cellsl
interquartil
rang
cellsl
tabl
similarli
anoth
studi
carri
huang
et
al
report
absolut
lymphocyt
count
patient
receiv
icu
care
cellsl
interquartil
rang
cellsl
risk
lymphocytopenia
may
affect
diseas
progress
covid
incid
anaemia
predict
baricitinib
therapi
incid
anaemia
report
nonsurvivor
due
covid
infect
initi
baricitinib
therapi
may
reduc
count
elev
creatin
kinas
observ
patient
baricitinib
therapi
although
median
valu
creatin
kinas
report
normal
rang
greatli
increas
critic
ill
patient
non
survivor
icu
patient
report
elev
creatin
kinas
level
one
critic
ill
patient
creatin
kinas
level
high
ul
elev
creatin
kinas
level
pose
risk
initi
baricitinib
therapi
limit
data
avail
potenti
effect
baricitinib
elderli
popul
year
fei
zhou
et
al
report
mortal
higher
elderli
patient
studi
report
increas
incid
respiratori
tract
infect
incid
infect
diseas
coinfect
one
common
threat
manag
novel
corona
viru
infect
also
risk
reactiv
latent
infect
patient
risk
tuberculosi
well
hepat
b
studi
conclud
baricitinib
therapi
constitut
reactiv
varicella
zoster
herp
simplex
epstein
barr
viru
strain
fei
zhou
et
al
report
patient
succumb
covid
experienc
secondari
infect
baricitinib
predict
earlier
may
ideal
drug
choic
covid
avail
therapeut
option
must
explor
order
prevent
mortal
case
